Chronic Liver Disease

Improving the prognosis of chronic viral hepatitis is a crucial goal in clinical treatment. Chronic hepatitis B (CHB) has a wide incidence, and its severe harm mainly stems from the progression from liver fibrosis to cirrhosis, leading to decompensated cirrhosis and liver cancer, seriously threatening the patient's life and health. Therefore, reversing early cirrhosis is of significant importance for reducing the risk of CHB-related liver diseases and death, representing an essential clinical need in CHB treatment. However, antiviral therapy alone has certain limitations, and traditional Chinese medicine (TCM) has enormous potential in combating liver fibrosis. At the recent 10th "Huaxia Shanghai Liver Disease Forum and Progress in Diagnosis and Treatment of Liver Failure and Its Complications," Dr. Chenghai Liu from the Liver Disease Research Institute of Shanghai Academy of Traditional Chinese Medicine, and the Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine shared the significant clinical benefits that the "dual antagonism" prevention and treatment strategy, combining antiviral therapy with TCM for anti-liver fibrosis, brings to CHB patients. The content has been compiled into an article for readers.